Drug development based on the immune system is well suited for cancer therapy because immune specificity yields low toxicity, while immune power can achieve a cure. PINS™ therapeutics activate the DC-APC innate immunity complex on an ongoing basis to produce and re-activate killer T-cells. Activation is selective for specific pathogens that are naturally abundant at the time of treatment. Animal trials with PINS™ are underway with clinical trials to follow for the treatment of HER- and HER+ breast cancer.